Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.

De Greef E, Hoffman I, D'Haens G, Van Biervliet S, Smets F, Scaillon M, Dewit O, Peeters H, Paquot I, Alliet P, Arts W, Hauser B, Vermeire S, Van Gossum A, Rahier JF, Etienne I, Louis E, Coche JC, Mahachie John J, Van Steen K, Veereman G; IBD working group of the Belgian Society of Pediatric Gastroenterology, Hepatology and Nutrition (BeSPGHAN); Belgian IBD Research and Development Group (BIRD).

Acta Gastroenterol Belg. 2012 Dec;75(4):425-31.

PMID:
23402086
2.

Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.

de Ridder L, Rings EH, Damen GM, Kneepkens CM, Schweizer JJ, Kokke FT, Benninga MA, Norbruis OF, Hoekstra JH, Gijsbers CF, Escher JC.

Inflamm Bowel Dis. 2008 Mar;14(3):353-8.

PMID:
18069674
3.

Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.

Kuin S, Stolte SB, van den Brink GR, Ponsioen CY, Fockens P, D'Haens GR, Löwenberg M.

Eur J Gastroenterol Hepatol. 2016 Feb;28(2):222-5. doi: 10.1097/MEG.0000000000000530.

PMID:
26566062
4.

Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.

Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G.

Can J Clin Pharmacol. 2001 Winter;8(4):188-98. Review.

PMID:
11743591
5.

Response to infliximab is related to disease duration in paediatric Crohn's disease.

Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, Dé Angelis GL, Guariso G, Martelossi S, Papadatou B, Barabino A.

Aliment Pharmacol Ther. 2003 Aug 15;18(4):425-31.

6.

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.

Kinney T, Rawlins M, Kozarek R, France R, Patterson D.

Am J Gastroenterol. 2003 Mar;98(3):608-12.

PMID:
12650795
7.
8.

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.

Lindsay J, Punekar YS, Morris J, Chung-Faye G.

Aliment Pharmacol Ther. 2008 Jul;28(1):76-87. doi: 10.1111/j.1365-2036.2008.03709.x. Epub 2008 Apr 11.

9.

Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up.

Wenzl HH, Reinisch W, Jahnel J, Stockenhuber F, Tilg H, Kirchgatterer A, Petritsch W.

Eur J Gastroenterol Hepatol. 2004 Aug;16(8):767-73.

PMID:
15256978
10.

Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease.

Regueiro M, El-Hachem S, Kip KE, Schraut W, Baidoo L, Watson A, Swoger J, Schwartz M, Barrie A, Pesci M, Binion D.

Dig Dis Sci. 2011 Dec;56(12):3610-5. doi: 10.1007/s10620-011-1785-9. Epub 2011 Jun 17.

PMID:
21681507
11.

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.

Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.

PMID:
25724455
12.

Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.

Sprakes MB, Ford AC, Suares NC, Warren L, Greer D, Donnellan CF, Jennings JS, Everett SM, Hamlin PJ.

Aliment Pharmacol Ther. 2010 Dec;32(11-12):1357-63. doi: 10.1111/j.1365-2036.2010.04482.x. Epub 2010 Oct 7.

13.

The cost-effectiveness of infliximab in Crohn's disease.

Smart C, Selinger CP.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):589-98. doi: 10.1586/14737167.2014.950235. Epub 2014 Aug 20. Review.

PMID:
25138162
14.

Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.

Kane SV, Chao J, Mulani PM.

Adv Ther. 2009 Oct;26(10):936-46. doi: 10.1007/s12325-009-0069-7. Epub 2009 Oct 16.

PMID:
19838649
15.

Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.

Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.

Am J Gastroenterol. 2000 Nov;95(11):3189-94.

PMID:
11095340
16.

Use of infliximab in pediatric patients with inflammatory bowel disease.

Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE.

Ann Pharmacother. 2001 Jul-Aug;35(7-8):823-8.

PMID:
11485127
17.

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS.

Am J Gastroenterol. 2003 Apr;98(4):833-8.

PMID:
12738464
18.

Infliximab use in luminal Crohn's disease.

Richter JA, Bickston SJ.

Gastroenterol Clin North Am. 2006 Dec;35(4):775-93. Review.

PMID:
17129813
19.

Infliximab for Crohn's disease: the first 500 patients followed up through 2009.

Seminerio JL, Loftus EV Jr, Colombel JF, Thapa P, Sandborn WJ.

Dig Dis Sci. 2013 Mar;58(3):797-806. doi: 10.1007/s10620-012-2405-z. Epub 2012 Sep 29.

PMID:
23053885
20.

Infliximab dependency in a national cohort of children with Crohn's disease.

Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A.

J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):40-5.

PMID:
16385252

Supplemental Content

Support Center